News
HKMPY
55.74
NaN%
--
Weekly Report: what happened at HKMPY last week (0609-0613)?
Weekly Report · 5d ago
Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities
TipRanks · 06/09 16:35
Weekly Report: what happened at HKMPY last week (0602-0606)?
Weekly Report · 06/09 10:00
Weekly Report: what happened at HKMPY last week (0526-0530)?
Weekly Report · 06/02 10:04
Weekly Report: what happened at HKMPY last week (0519-0523)?
Weekly Report · 05/26 10:04
RBC Capital Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 05/20 06:35
Weekly Report: what happened at HKMPY last week (0512-0516)?
Weekly Report · 05/19 10:00
Weekly Report: what happened at HKMPY last week (0505-0509)?
Weekly Report · 05/12 10:00
*Hikma Pharmaceuticals Will Continue to Defend Itself Against Any Other Litigation
Dow Jones · 05/08 07:24
*Hikma Pharmaceuticals: Settlement Not Admission of Wrongdoing or Liability
Dow Jones · 05/08 07:24
*Hikma Pharmaceuticals: Settlement Fee Subject to Court Approval
Dow Jones · 05/08 07:23
*Hikma Pharmaceuticals to Pay Up to $50M in Cash Under Pact
Dow Jones · 05/08 07:22
*Hikma Pharmaceuticals: Pact Resolves Most of Xyrem Cases in US
Dow Jones · 05/08 07:22
Weekly Report: what happened at HKMPY last week (0428-0502)?
Weekly Report · 05/05 10:01
Weekly Report: what happened at HKMPY last week (0421-0425)?
Weekly Report · 04/28 10:05
Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie
TipRanks · 04/24 08:45
Weekly Report: what happened at HKMPY last week (0414-0418)?
Weekly Report · 04/21 10:05
Weekly Report: what happened at HKMPY last week (0407-0411)?
Weekly Report · 04/14 10:00
Hikma Pharmaceuticals: Strategic Growth and Resilience Amid Market Opportunities
TipRanks · 04/10 06:35
Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk
Dow Jones · 04/08 08:20
More
Webull provides a variety of real-time HKMPY stock news. You can receive the latest news about Hikma Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About HKMPY
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.